Clinical trial · Observational
Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study
Preoperative Evaluation of Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study
NCT01455610CI-TRIAL-00005663unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectability of pancreatic head cancer with contrasted-enhanced MDCT and its various post processing techniques, taking operational and pathological records as the gold standard.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of Head of Pancreas | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with (or suspected) pancreatic head cancer * Being examined by contrasted-enhanced MDCT * Receiving surgical treatment (including palliative surgery) in all research centers Exclusion Criteria: * Patients having (or suspected) pregnancy or breast-feeding * Patients having allergic reactions to iodinated contrast agents or Hypersensitivity reactions to allergens(including drugs) * Patients receiving ERCP before contrasted-enhanced MDCT examination * Patients without surgery because of a high degree of surgical risk
References
Publications (0)
Data not yet available
No reference posted for this study.